Treatment of Lead-Exposed Children Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

780

Participants

Timeline

Start Date

July 15, 1994

Primary Completion Date

August 29, 2007

Study Completion Date

June 10, 2015

Conditions
Lead Exposure
Interventions
DRUG

Succimer

Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.

DRUG

Placebo

Trial Locations (4)

19104

Childrens Hospital, Philadelphia, Philadelphia

21205

Kennedy Krieger Institute, Baltimore

07103

University of Medicine and Dentistry of New Jersey, Newark

43205-2696

Childrens Hospital, Columbus, Columbus

All Listed Sponsors
lead

National Institute of Environmental Health Sciences (NIEHS)

NIH

NCT00342849 - Treatment of Lead-Exposed Children Trial | Biotech Hunter | Biotech Hunter